

	Khambata-Ford (n=68)	INSERM (n=85)
KRAS mutant	26 (39%)	0%
RECIST		
PD	36 (52%)	3 (3%)
SD	17 (25%)	37 (44%)
PR	4 (6%)	32 (38%)
CR	0	13 (15%)
UTD	11	0
PFS (median, 95%) weeks	8.5 [4.4 - 35.0]	28.8 [ 8 - 64.3]

**STable 2:** Characteristics of the 2 metastatic CRC datasets used for evaluation of prediction of PFS.